Presage Biosciences is a leader in the identification of clinically viable oncology drug combinations. The Company’s proprietary technology platform allows for the rapid, reliable assessment of cancer therapeutics in an in-vivo setting, providing the first side-by-side comparison of multiple drugs and drug combinations within a single living tumor.

This technology heralds a new, innovative approach to selecting optimal drug candidates and efficiently advancing cancer therapeutics to the market. Through select research partnerships with oncology focused drug development companies, Presage offers clinically relevant, decision-making data for selection and prioritization of drug candidates as well as the rapid assessment of drug combination strategies to support improved patient treatment.

Presage is a privately held company led by an experienced management team and is headquartered in Seattle.